Symbols / KNSA Stock $59.13 -0.61% Kiniksa Pharmaceuticals International, plc

Healthcare • Drug Manufacturers - Specialty & Generic • United Kingdom • NMS
KNSA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO —
Exch · Country NMS · United Kingdom
Market Cap 4.55B
Enterprise Value 4.09B
Income 73.06M
Sales 754.04M
FCF (ttm) 117.57M
Book/sh 8.22
Cash/sh 6.08
Employees 366
Insider 10d —
IPO May 25, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 64.98
Forward P/E 33.64
PEG —
P/S 6.03
P/B 7.19
P/C —
EV/EBITDA 43.10
EV/Sales 5.42
Quick Ratio 3.14
Current Ratio 3.79
Debt/Eq 1.49
LT Debt/Eq —
EPS (ttm) 0.91
EPS next Y 1.76
EPS Growth 145.50%
Revenue Growth 55.50%
EPS Gr Q/Q 164.60%
Rev Gr Q/Q —
Earnings (next) 2026-07-28
Earnings (prior) 2026-04-28
ROA 8.18%
ROE 13.74%
ROIC —
Gross Margin 54.65%
Oper. Margin 13.66%
Profit Margin 9.69%
Shs Outstand 46.30M
Shs Float 39.32M
Insider Own 3.58%
Instit Own 102.75%
Short Float 8.01%
Short Ratio 4.95
Short Interest 3.04M
52W High 61.12
vs 52W High -3.26%
52W Low 26.27
vs 52W Low 125.09%
Beta 0.12
Impl. Vol. 0.78%
Rel Volume 1.56
Avg Volume 672.65K
Volume 1.05M
Target (mean) $63.50
Tgt Median $62.00
Tgt Low $57.00
Tgt High $72.00
# Analysts 8
Recom None
Prev Close $59.49
Price $59.13
Change -0.61%
About

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$63.50
Mean price target
2. Current target
$59.13
Latest analyst target
3. DCF / Fair value
$45.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$59.13
Low
$57.00
High
$72.00
Mean
$63.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main Canaccord Genuity Buy → Buy $64
2026-04-29 main Citigroup Buy → Buy $60
2026-04-29 main Wedbush Outperform → Outperform $59
2026-04-29 main Wells Fargo Overweight → Overweight $57
2026-04-28 main Jefferies Buy → Buy $71
2026-04-16 main Wedbush Outperform → Outperform $58
2026-02-25 main Wells Fargo Overweight → Overweight $53
2026-02-25 main Wedbush Outperform → Outperform $53
2026-02-19 init Canaccord Genuity — → Buy $62
2026-01-13 main Wedbush Outperform → Outperform $50
2025-10-29 main Goldman Sachs Buy → Buy $55
2025-10-17 main Citigroup Buy → Buy $50
2025-10-13 main Wedbush Outperform → Outperform $44
2025-09-29 init TD Cowen — → Buy $60
2025-09-25 main Wells Fargo Overweight → Overweight $45
2025-07-29 main Jefferies Buy → Buy $54
2025-07-09 main Wells Fargo Overweight → Overweight $42
2025-04-29 main Jefferies Buy → Buy $45
2025-04-16 reit Wedbush Outperform → Outperform $34
2025-03-13 init Citigroup — → Buy $40
News
RSS: Latest KNSA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-01 PATEL SANJIV K Chief Executive Officer — 900,000 — —
2026-05-29 QUART BARRY D Director — 2,799 — —
2026-05-29 COLE GORDON BRADLEY Director — 2,799 — —
2026-05-29 POPOVITS KIMBERLY J Director — 2,799 — —
2026-05-29 BAKER BROS ADVISORS L.P. Unknown — 12,156 $0.00 $0
2026-05-29 MALLEY THOMAS ROBERT Director — 2,799 — —
2026-05-29 LEVY RICHARD S Director — 2,799 — —
2026-05-29 MCCAIN TRACEY LORENE Director — 2,799 — —
2026-05-01 PATEL SANJIV K Chief Executive Officer — 48,565 $54.02 $2,623,481
2026-05-01 PATEL SANJIV K Chief Executive Officer — 48,565 $30.93 $1,502,115
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
677.56
+60.09%
423.24
+56.60%
270.26
+22.74%
220.18
Operating Revenue
677.56
+60.09%
423.24
+56.60%
270.26
+22.74%
220.18
Cost Of Revenue
307.22
+404.38%
60.91
+82.33%
33.41
+45.91%
22.89
Reconciled Cost Of Revenue
307.22
+404.38%
60.91
+82.33%
33.41
+45.91%
22.89
Gross Profit
370.35
+2.21%
362.33
+52.98%
236.85
+20.06%
197.28
Operating Expense
293.12
-28.15%
407.94
+55.68%
262.05
+39.75%
187.51
Research And Development
96.85
-13.23%
111.62
+46.69%
76.10
+16.20%
65.49
Selling General And Administration
196.27
+16.82%
168.01
+29.81%
129.43
+32.13%
97.95
Other Operating Expenses
—
128.31
+127.00%
56.52
+134.82%
24.07
Total Expenses
600.34
+28.04%
468.86
+58.69%
295.45
+40.42%
210.41
Operating Income
77.22
+269.28%
-45.62
-81.04%
-25.20
-357.81%
9.77
Total Operating Income As Reported
77.22
+269.28%
-45.62
-81.04%
-25.20
-357.81%
9.77
EBITDA
78.78
+279.36%
-43.92
-92.17%
-22.86
-287.72%
12.18
Normalized EBITDA
78.78
+279.36%
-43.92
-92.17%
-22.86
-287.72%
12.18
Reconciled Depreciation
1.55
-8.32%
1.70
-27.60%
2.34
-2.54%
2.40
EBIT
77.22
+269.28%
-45.62
-81.04%
-25.20
-357.81%
9.77
Net Income
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Pretax Income
88.87
+345.82%
-36.15
-117.10%
-16.65
-251.02%
11.03
Net Non Operating Interest Income Expense
—
—
—
1.25
Net Interest Income
—
—
—
1.25
Interest Income Non Operating
—
—
—
1.25
Interest Income
—
—
—
1.25
Other Income Expense
11.65
+23.07%
9.46
+10.77%
8.54
+581.88%
1.25
Other Non Operating Income Expenses
11.65
+23.07%
9.46
+10.77%
8.54
+581.88%
1.25
Tax Provision
29.86
+324.13%
7.04
+122.91%
-30.74
+82.17%
-172.34
Tax Rate For Calcs
0.00
+59.52%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Net Income From Continuing Operation Net Minority Interest
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Net Income From Continuing And Discontinued Operation
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Net Income Continuous Operations
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Normalized Income
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Net Income Common Stockholders
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Diluted EPS
0.75
+225.00%
-0.60
-400.00%
0.20
-92.31%
2.60
Basic EPS
0.80
+233.33%
-0.60
-400.00%
0.20
-92.42%
2.64
Basic Average Shares
74.20
+3.89%
71.42
+1.95%
70.06
+0.98%
69.38
Diluted Average Shares
78.98
+10.58%
71.42
-0.69%
71.92
+2.13%
70.42
Diluted NI Availto Com Stockholders
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
763.63
+31.54%
580.55
+10.30%
526.32
+14.50%
459.67
Current Assets
527.18
+58.88%
331.80
+20.09%
276.30
+13.67%
243.06
Cash Cash Equivalents And Short Term Investments
414.07
+69.96%
243.63
+18.05%
206.37
+8.27%
190.61
Cash And Cash Equivalents
165.60
-9.80%
183.58
+70.05%
107.95
-12.03%
122.72
Other Short Term Investments
248.48
+313.81%
60.05
-38.99%
98.42
+44.96%
67.89
Receivables
15.59
-62.63%
41.72
+96.20%
21.27
+4.68%
20.32
Accounts Receivable
15.59
-62.63%
41.72
+96.20%
21.27
+67.98%
12.66
Other Receivables
—
—
—
7.66
Inventory
54.90
+108.22%
26.36
-15.29%
31.12
+44.09%
21.60
Raw Materials
9.97
-0.04%
9.97
0.00
0.00
Work In Process
29.40
0.00
-100.00%
18.26
+189.26%
6.31
Finished Goods
20.55
-3.25%
21.25
+65.16%
12.86
-15.85%
15.29
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
—
—
Other Current Assets
42.61
+112.18%
20.08
+14.52%
17.54
+66.44%
10.54
Total Non Current Assets
236.46
-4.94%
248.75
-0.51%
250.03
+15.43%
216.61
Net PPE
11.75
+6.45%
11.04
-12.85%
12.66
+79.82%
7.04
Gross PPE
18.98
-1.31%
19.23
-5.96%
20.45
+47.10%
13.90
Accumulated Depreciation
-7.23
+11.75%
-8.19
-5.24%
-7.79
-13.50%
-6.86
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.27
-51.42%
0.56
-6.80%
0.60
+5.98%
0.57
Construction In Progress
0.26
+64.52%
0.15
+1092.31%
0.01
0.00
Other Properties
13.81
-5.28%
14.58
-8.30%
15.90
+69.14%
9.40
Leases
4.64
+18.01%
3.93
+0.00%
3.93
+0.00%
3.93
Goodwill And Other Intangible Assets
15.25
-6.15%
16.25
-5.80%
17.25
-5.48%
18.25
Other Intangible Assets
15.25
-6.15%
16.25
-5.80%
17.25
-5.48%
18.25
Non Current Deferred Assets
198.15
-6.16%
211.15
-3.71%
219.28
+18.22%
185.50
Non Current Deferred Taxes Assets
198.15
-6.16%
211.15
-3.71%
219.28
+18.22%
185.50
Other Non Current Assets
11.31
+9.62%
10.31
+1147.28%
0.83
-85.80%
5.82
Total Liabilities Net Minority Interest
196.03
+37.93%
142.12
+62.45%
87.48
+37.72%
63.52
Current Liabilities
139.18
+38.33%
100.62
+58.05%
63.67
+35.27%
47.07
Payables And Accrued Expenses
92.63
+41.40%
65.50
+77.24%
36.96
+37.92%
26.80
Payables
2.03
-0.54%
2.04
-75.27%
8.25
+4.39%
7.90
Accounts Payable
2.03
-0.54%
2.04
-75.27%
8.25
+4.39%
7.90
Current Accrued Expenses
90.60
+42.75%
63.47
+121.04%
28.71
+51.93%
18.90
Pensionand Other Post Retirement Benefit Plans Current
21.44
+25.76%
17.05
+6.84%
15.95
+42.28%
11.21
Current Debt And Capital Lease Obligation
2.99
+49.87%
1.99
-11.54%
2.25
-31.75%
3.30
Current Capital Lease Obligation
2.99
+49.87%
1.99
-11.54%
2.25
-31.75%
3.30
Current Deferred Liabilities
—
0.00
-100.00%
0.31
0.00
Current Deferred Revenue
—
0.00
-100.00%
0.31
0.00
Other Current Liabilities
22.13
+37.67%
16.08
+96.23%
8.19
+42.39%
5.75
Total Non Current Liabilities Net Minority Interest
56.84
+36.98%
41.50
+74.23%
23.82
+44.72%
16.46
Long Term Debt And Capital Lease Obligation
6.51
-17.20%
7.86
-21.42%
10.01
+282.16%
2.62
Long Term Capital Lease Obligation
6.51
-17.20%
7.86
-21.42%
10.01
+282.16%
2.62
Non Current Deferred Liabilities
31.81
+0.00%
31.81
+166.11%
11.95
-0.38%
12.00
Non Current Deferred Revenue
31.81
+0.00%
31.81
+166.11%
11.95
-0.38%
12.00
Other Non Current Liabilities
18.52
+916.02%
1.82
-1.88%
1.86
+1.03%
1.84
Stockholders Equity
567.61
+29.46%
438.44
-0.09%
438.84
+10.78%
396.15
Common Stock Equity
567.61
+29.46%
438.44
-0.09%
438.84
+10.78%
396.15
Capital Stock
0.02
+5.00%
0.02
+0.00%
0.02
+5.26%
0.02
Common Stock
0.02
+5.00%
0.02
+0.00%
0.02
+5.26%
0.02
Share Issued
76.29
+5.21%
72.52
+2.92%
70.46
+1.09%
69.70
Ordinary Shares Number
76.29
+5.21%
72.52
+2.92%
70.46
+1.09%
69.70
Additional Paid In Capital
1,029.75
+7.30%
959.72
+4.69%
916.76
+3.23%
888.12
Retained Earnings
-462.14
+11.32%
-521.14
-9.04%
-477.95
+2.86%
-492.03
Gains Losses Not Affecting Retained Earnings
-0.03
+84.66%
-0.16
-2816.67%
0.01
-86.36%
0.04
Other Equity Adjustments
-0.03
+84.66%
-0.16
-2816.67%
0.01
-86.36%
0.04
Total Equity Gross Minority Interest
567.61
+29.46%
438.44
-0.09%
438.84
+10.78%
396.15
Total Capitalization
567.61
+29.46%
438.44
-0.09%
438.84
+10.78%
396.15
Working Capital
387.99
+67.83%
231.18
+8.72%
212.63
+8.49%
195.99
Invested Capital
567.61
+29.46%
438.44
-0.09%
438.84
+10.78%
396.15
Total Debt
9.50
-3.63%
9.86
-19.60%
12.26
+107.10%
5.92
Capital Lease Obligations
9.50
-3.63%
9.86
-19.60%
12.26
+107.10%
5.92
Net Tangible Assets
552.36
+30.83%
422.19
+0.14%
421.59
+11.56%
377.90
Tangible Book Value
552.36
+30.83%
422.19
+0.14%
421.59
+11.56%
377.90
Inventories Adjustments Allowances
-5.03
-3.56%
-4.85
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
137.99
+437.14%
25.69
+93.14%
13.30
+129.05%
5.81
Cash Flow From Continuing Operating Activities
137.99
+437.14%
25.69
+93.14%
13.30
+129.05%
5.81
Net Income From Continuing Operations
59.01
+236.61%
-43.19
-406.68%
14.08
-92.32%
183.36
Depreciation Amortization Depletion
1.55
-8.32%
1.70
-27.60%
2.34
-2.54%
2.40
Depreciation And Amortization
1.55
-8.32%
1.70
-27.60%
2.34
-2.54%
2.40
Other Non Cash Items
3.67
+16.90%
3.14
+2.69%
3.05
+0.43%
3.04
Stock Based Compensation
37.00
+20.56%
30.69
+13.05%
27.15
+8.08%
25.12
Deferred Tax
13.00
+59.89%
8.13
+124.07%
-33.79
+81.78%
-185.50
Deferred Income Tax
13.00
+59.89%
8.13
+124.07%
-33.79
+81.78%
-185.50
Operating Gains Losses
-0.12
-400.00%
-0.02
-113.41%
0.18
+442.42%
0.03
Gain Loss On Sale Of PPE
-0.12
-400.00%
-0.02
-113.41%
0.18
+442.42%
0.03
Change In Working Capital
24.79
-0.07%
24.81
+1737.70%
1.35
+105.98%
-22.57
Change In Receivables
26.13
+227.73%
-20.46
-2053.47%
-0.95
+94.18%
-16.33
Changes In Account Receivables
26.13
+227.73%
-20.46
-137.72%
-8.61
+0.80%
-8.68
Change In Inventory
-28.53
-699.64%
4.76
+149.96%
-9.52
+46.87%
-17.92
Change In Prepaid Assets
-22.48
-729.56%
-2.71
+61.65%
-7.07
-83.18%
-3.86
Change In Payables And Accrued Expense
37.64
+0.58%
37.42
+116.48%
17.29
+644.49%
2.32
Change In Accrued Expense
37.50
-14.25%
43.73
+158.14%
16.94
+556.73%
-3.71
Change In Payable
0.14
+102.25%
-6.31
-1917.29%
0.35
-94.25%
6.03
Change In Account Payable
0.14
+102.25%
-6.31
-1917.29%
0.35
-94.25%
6.03
Change In Other Working Capital
—
19.55
+7390.42%
0.26
-97.82%
12.00
Change In Other Current Assets
-1.21
+87.57%
-9.73
-312.37%
4.58
+72.72%
2.65
Change In Other Current Liabilities
13.24
+429.53%
-4.02
-23.97%
-3.24
-125.45%
-1.44
Investing Cash Flow
-188.99
-601.68%
37.67
+227.46%
-29.56
-265.90%
-8.08
Cash Flow From Continuing Investing Activities
-188.99
-601.68%
37.67
+227.46%
-29.56
-265.90%
-8.08
Net PPE Purchase And Sale
-1.57
-522.22%
-0.25
-93.85%
-0.13
-828.57%
-0.01
Purchase Of PPE
-1.57
-466.06%
-0.28
-113.08%
-0.13
-23.81%
-0.10
Sale Of PPE
0.00
-100.00%
0.03
0.00
-100.00%
0.09
Capital Expenditure
-1.57
-466.06%
-0.28
-113.08%
-0.13
-23.81%
-0.10
Net Investment Purchase And Sale
-187.43
-594.21%
37.92
+228.87%
-29.43
-264.92%
-8.06
Purchase Of Investment
-386.92
-91.53%
-202.01
+1.42%
-204.93
-50.84%
-135.86
Sale Of Investment
199.49
-16.86%
239.94
+36.71%
175.51
+37.33%
127.80
Net Intangibles Purchase And Sale
—
—
0.00
0.00
Purchase Of Intangibles
—
—
0.00
0.00
Financing Cash Flow
33.02
+169.22%
12.27
+720.47%
1.50
-40.58%
2.52
Cash Flow From Continuing Financing Activities
33.02
+169.22%
12.27
+720.47%
1.50
-40.58%
2.52
Net Common Stock Issuance
-7.73
-55.10%
-4.98
-125.93%
-2.21
-144.84%
-0.90
Common Stock Payments
-7.73
-55.10%
-4.98
-125.93%
-2.21
-144.84%
-0.90
Repurchase Of Capital Stock
-7.73
-55.10%
-4.98
-125.93%
-2.21
-144.84%
-0.90
Proceeds From Stock Option Exercised
40.75
+136.25%
17.25
+366.09%
3.70
+8.31%
3.42
Changes In Cash
-17.98
-123.78%
75.63
+612.34%
-14.76
-6124.90%
0.24
Beginning Cash Position
183.58
+70.05%
107.95
-12.03%
122.72
+0.20%
122.47
End Cash Position
165.60
-9.80%
183.58
+70.05%
107.95
-12.03%
122.72
Free Cash Flow
136.42
+436.82%
25.41
+92.94%
13.17
+130.99%
5.70
Income Tax Paid Supplemental Data
3.01
+50.37%
2.00
-64.26%
5.61
-47.56%
10.69
Amortization Of Securities
-0.92
-307.71%
0.44
+141.29%
-1.07
-1202.44%
-0.08
Common Stock Issuance
—
—
—
3.42
Issuance Of Capital Stock
—
—
—
3.42
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category